
|Videos|May 7, 2021
Analysis of 24-month data from the PALADIN study
Author(s)David Hutton, OT Staff Reports
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Advertisement
Michael A. Singer, MD, of the Medical Center Ophthalmology Associates in San Antonio, Texas, speaks on the highlights of his presentation focusing on intraocular pressure (IOP) in the PALADIN 24-month data intravitreal steroid (ILUVIEN), presented during ARVO 2021.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
2
Timely interventions can protect vision in patients with GA
3
Monitoring MacTel: Why BCVA does not tell the whole story
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5










































